RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

We'll likely get a Monday press release of the CX-1739 results, and then Dr. Manuso will discuss those results at the R+R Investor Conference (4:15 PM). Based on the previous strong efficacy seen in the CX-717 RD trial, the odds for success in this CX-1739 trial should be good. CX-1739 is approx 3 times more potent than CX-717.

I'm hoping there is some financing news soon, and will also be interested in finding out what they meant by 'strategic initiatives' in today's press release. Might just be a general buzz word/phrase but would be nice to get a partner or large investor in the company.

They need to get some real funding in place and then the management's turnaround of the company is nearly complete and the road will be clear for more clinical trials, including a CX-1739 Central Sleep Apnea trial. That trial will be extremely interesting based on the phenomenal efficacy shown in the Central Sleep Apnea cohort in the first CX-1739 SA trial (basically complete reversal of symptoms in that cohort). The efficacy in the Mixed Sleep Apnea cohort (those with both Obstructive SA and Central/brain mediated SA components) was also good.